| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 10.02.
| BioSante LibiGel study needs no modification, says DMC | | 42 | Pharma Bus Review |
| 10.02.
| Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc. | | 119 | PR Newswire |
| NEW YORK, Feb. 9, 2012 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at BioSante Pharmaceuticals, Inc. ("BioSante" or the...
Mehr lesen zu:
Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc. | |
| 09.02.
| BioSante: LibiGel Lives On, FDA Word On Bio-T-Gel May Come At Any Time | | 11 | Seeking Alpha |
| 09.02.
| Traders Get Bullish on Shares of Biosante Pharmaceuticals, Shares Up 8.0% | | 3 | SmarTrend |
| 09.02.
| BioSante Pharma Reveals Positive LibiGel Safety Data For Phase III Program | | 74 | AFX News |
| WASHINGTON (dpa-AFX) - BioSante Pharmaceuticals Inc. (BPAX) said the
independent Data Monitoring Committee or DMC has completed the eighth unblinded
review of the LibiGel Phase III cardiovascular...
Mehr lesen zu:
BioSante Pharma Reveals Positive LibiGel Safety Data For Phase III Program | |
| 09.02.
| BioSante (BPAX) Reports Positive Review from Independent DMC for LibiGel Phase III | | 3 | StreetInsider.com |
| 09.02.
| BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review for Phase III Program | | 1 | Benzinga.com |
| 09.02.
| BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review for Phase III Program | | 40 | Business Wire |
| BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the
independent Data Monitoring Committee (DMC) has completed the eighth
unblinded review of the LibiGel...
Mehr lesen zu:
BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review for Phase III Program | |
| 08.02.
| UPDATE: BioSante Exchanges $5 Million Aggregate Principal Amount of Convertible Senior Notes for 6.7 Million Shares of Common Stock | | 12 | Benzinga.com |
| 08.02.
| BioSante Exchanges $5 Million Aggregate Principal Amount of Convertible Senior Notes for 6.7 Million Shares of Common Stock | | 54 | Business Wire |
| BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the
company has entered into a privately-negotiated securities exchange
agreement with a holder of...
Mehr lesen zu:
BioSante Exchanges $5 Million Aggregate Principal Amount of Convertible Senior Notes for 6.7 Million Shares of Common Stock | |
| 08.02.
| BioSante (BPAX) Enters Agreement to Cancel $5M of Debt, Will Issue 6.7M Common in Deal | | 15 | StreetInsider.com |
| 08.02.
| Investor Alert: Kahn Swick & Foti, LLC and Partner Former Louisiana Attorney General Remind Investors With Large Financial Interests of Lead Plaintiff Deadline in Lawsuit Against BioSante Pharmaceuticals, Inc. | | 86 | Business Wire |
| Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney
General of Louisiana, Charles C. Foti, Jr., remind investors that they
have until April 6, 2012 to...
Mehr lesen zu:
Investor Alert: Kahn Swick & Foti, LLC and Partner Former Louisiana Attorney General Remind Investors With Large Financial Interests of Lead Plaintiff Deadline in Lawsuit Against BioSante Pharmaceuticals, Inc. | |
| 07.02.
| Possible Bearish Inside Day Candle Pattern Detected for Biosante Pharmaceuticals | | 12 | SmarTrend |
| 07.02.
| Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) | | 44 | MarketWire |
| OKLAHOMA CITY, OK -- (Marketwire) -- 02/07/12 -- On February 3, 2012, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois against BioSante Pharmaceuticals...
Mehr lesen zu:
Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) | |
| 07.02.
| Perception, Opportunity in Volatility - Research & Analysis on Dendreon Corporation and BioSante Pharmaceuticals, Inc. | | 36 | MarketWire |
| HONG KONG -- (Marketwire) -- 02/07/12 -- This morning, www.MarketFoundations.com announced new reports highlighting Dendreon Corporation (NASDAQ: DNDN) and BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)....
Mehr lesen zu:
Perception, Opportunity in Volatility - Research & Analysis on Dendreon Corporation and BioSante Pharmaceuticals, Inc. | |
| 06.02.
| Hot Stock: Biosante Pharmaceuticals, Shares Gain 15.4% | | 31 | SmarTrend |
| 06.02.
| BioSante Has Potential To Double Soon | | 34 | Seeking Alpha |
| 06.02.
| Robbins Umeda LLP Announces Class Action Suit Against BioSante Pharmaceuticals, Inc. | | 40 | Business Wire |
| Shareholder rights firm Robbins
Umeda LLP, announces that the firm commenced a class action lawsuit
on February 3, 2012 in the U.S. District Court for the Northern District...
Mehr lesen zu:
Robbins Umeda LLP Announces Class Action Suit Against BioSante Pharmaceuticals, Inc. | |
| 01.02.
| Will Biosante's Libigel Make A Comeback? | | 33 | Seeking Alpha |
| 31.01.
| Shares of BioSante and Cell Therapeutics on the Upswing as Biotech Sector Rallies / Five Star Equities Provides Stock Research on BioSante Pharmaceuticals & Cell Therapeutics | | 87 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 01/31/12 -- Biotechnology stocks have been on a tear this month, gaining an impressive 11 percent. Reuters recently released an article arguing health-care costs are...
Mehr lesen zu:
Shares of BioSante and Cell Therapeutics on the Upswing as Biotech Sector Rallies / Five Star Equities Provides Stock Research on BioSante Pharmaceuticals & Cell Therapeutics | |
